

James Brugarolas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6499207/publications.pdf>

Version: 2024-02-01

135
papers

11,756
citations

53794

45
h-index

29157

104
g-index

140
all docs

140
docs citations

140
times ranked

16641
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation-induced cell cycle arrest compromised by p21 deficiency. <i>Nature</i> , 1995, 377, 552-557.	27.8	1,218
2	Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. <i>Genes and Development</i> , 2004, 18, 2893-2904.	5.9	1,166
3	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. <i>Nature Medicine</i> , 2004, 10, 594-601.	30.7	913
4	BAP1 loss defines a new class of renal cell carcinoma. <i>Nature Genetics</i> , 2012, 44, 751-759.	21.4	791
5	Targeting renal cell carcinoma with a HIF-2 antagonist. <i>Nature</i> , 2016, 539, 112-117.	27.8	521
6	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. <i>Lancet Oncology</i> , The, 2013, 14, 159-167.	10.7	383
7	Regulation of TFEB and V-ATPases by mTORC1. <i>EMBO Journal</i> , 2011, 30, 3242-3258.	7.8	379
8	The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. <i>EMBO Journal</i> , 2018, 37, .	7.8	332
9	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2015, 47, 13-21.	21.4	310
10	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 867-874.	1.6	290
11	Molecular Genetics of Clear-Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1968-1976.	1.6	252
12	Renal-Cell Carcinoma Molecular Pathways and Therapies. <i>New England Journal of Medicine</i> , 2007, 356, 185-187.	27.0	251
13	Multistep regulation of TFEB by MTORC1. <i>Autophagy</i> , 2017, 13, 464-472.	9.1	162
14	Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. <i>Cancer Cell</i> , 2004, 6, 7-10.	16.8	160
15	A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 137ra75.	12.4	159
16	SCINA: Semi-Supervised Analysis of Single Cells in Silico. <i>Genes</i> , 2019, 10, 531.	2.4	150
17	p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells. <i>Journal of Cell Biology</i> , 1998, 141, 503-514.	5.2	145
18	Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. <i>Cancer Discovery</i> , 2020, 10, 1103-1120.	9.4	144

#	ARTICLE	IF	CITATIONS
19	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. <i>Cancer Discovery</i> , 2018, 8, 1142-1155.	9.4	138
20	A Novel Germline Mutation in <i>BAP1</i> Predisposes to Familial Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2013, 11, 1061-1071.	3.4	135
21	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1059-1067.	4.1	129
22	Modeling Renal Cell Carcinoma in Mice: <i>Bap1</i> and <i>Pbrm1</i> Inactivation Drive Tumor Grade. <i>Cancer Discovery</i> , 2017, 7, 900-917.	9.4	128
23	<i>Bap1</i> is essential for kidney function and cooperates with <i>Vhl</i> in renal tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16538-16543.	7.1	123
24	The von Hippel-Lindau Tumor Suppressor Gene. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 390-398.	2.0	123
25	Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. <i>Nature Immunology</i> , 2013, 14, 61-71.	14.5	122
26	HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 793-803.	7.0	117
27	Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications. <i>Nature Protocols</i> , 2013, 8, 2240-2255.	12.0	114
28	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. <i>Journal of Urology</i> , 2016, 195, 180-187.	0.4	113
29	Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2011, 9, 1255-1265.	3.4	97
30	PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 324-332.	2.0	94
31	Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm. <i>Cancer Research</i> , 2013, 73, 4173-4179.	0.9	80
32	Hypoxia-inducible factor 1 α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. <i>Journal of Biological Chemistry</i> , 2017, 292, 9382-9393.	3.4	80
33	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019, 76, 754-764.	1.9	80
34	Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. <i>Nature Chemical Biology</i> , 2011, 7, 712-719.	8.0	70
35	Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia. <i>Molecular and Cellular Biology</i> , 2011, 31, 1870-1884.	2.3	70
36	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.4	69

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 91-100.	0.8	67
38	Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 367-375.	0.8	65
39	Structural Analysis and Functional Implications of the Negative mTORC1 Regulator REDD1. <i>Biochemistry</i> , 2010, 49, 2491-2501.	2.5	61
40	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	59
41	Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. <i>Human Molecular Genetics</i> , 2009, 18, 4428-4441.	2.9	58
42	Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β^2 -Catenin. <i>Cell Reports</i> , 2015, 13, 495-503.	6.4	57
43	Sirolimus and Temsirolimus for Epithelioid Angiomyolipoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e65-e68.	1.6	56
44	Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing. <i>Nature Protocols</i> , 2014, 9, 1848-1859.	12.0	55
45	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , 2016, 29, 34-42.	5.5	55
46	Pancreatic tropism of metastatic renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	5.0	55
47	Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 614-614.	1.6	55
48	PD-L1 detection using ^{89}Zr -atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
49	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e25-e36.	1.9	44
50	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 924-931.	1.6	42
51	Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. <i>Nature Reviews Urology</i> , 2011, 8, 165-171.	3.8	41
52	Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e9-23.e14.	1.6	40
53	Tumor neoantigenicity assessment with CSIN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. <i>Science Immunology</i> , 2020, 5, .	11.9	39
54	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus Safety Lead-in Results of a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1135-1142.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 645-645.	1.6	36
56	Hepatic mTORC1 Opposes Impaired Insulin Action to Control Mitochondrial Metabolism in Obesity. Cell Reports, 2016, 16, 508-519.	6.4	34
57	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3706-3713.	1.6	34
58	Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Modern Pathology, 2022, 35, 333-343.	5.5	34
59	Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. Molecular and Cellular Biology, 2016, 36, 1836-1855.	2.3	33
60	Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. EBioMedicine, 2020, 51, 102526.	6.1	33
61	Development of a Patient-specific Tumor Mold Using Magnetic Resonance Imaging and 3-Dimensional Printing Technology for Targeted Tissue Procurement and Radiomics Analysis of Renal Masses. Urology, 2018, 112, 209-214.	1.0	32
62	TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy. Cell Cycle, 2011, 10, 3987-3988.	2.6	31
63	Prolonged Survival of a Patient With Papillary Renal Cell Carcinoma and Brain Metastases Using Pazopanib. Journal of Clinical Oncology, 2013, 31, e114-e117.	1.6	31
64	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. Clinical Genitourinary Cancer, 2016, 14, e585-e594.	1.9	31
65	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology, 2018, 7, e1440168.	4.6	31
66	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation, 2018, 25, 1885-1904.	11.2	31
67	Ablation of a Site of Progression With Stereotactic Body Radiation Therapy Extends Sunitinib Treatment From 14 to 22 Months. Journal of Clinical Oncology, 2013, 31, e401-e403.	1.6	29
68	High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget, 2015, 6, 16951-16962.	1.8	28
69	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urology, 2017, 17, 19.	1.4	26
70	Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss. Advances in Anatomic Pathology, 2021, 28, 251-257.	4.3	26
71	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. European Urology Oncology, 2022, 5, 216-224.	5.4	26
72	Personalized Management of Advanced Kidney Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 330-341.	3.8	25

#	ARTICLE	IF	CITATIONS
73	Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e273-e280.	1.9	25
74	Determinants of renal cell carcinoma invasion and metastatic competence. <i>Nature Communications</i> , 2021, 12, 5760.	12.8	25
75	REDD1/DDIT4-Independent mTORC1 Inhibition and Apoptosis by Glucocorticoids in Thymocytes. <i>Molecular Cancer Research</i> , 2014, 12, 867-877.	3.4	24
76	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15Year experience and lessons learned. <i>BMC Urology</i> , 2016, 16, 43.	1.4	24
77	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
78	The Evolution of Angiogenic and Inflamed Tumors: The Renal Cancer Paradigm. <i>Cancer Cell</i> , 2020, 38, 771-773.	16.8	23
79	Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Receptor Inactivation by Sunitinib Results in Tsc1/Tsc2-Dependent Inhibition of TORC1. <i>Molecular and Cellular Biology</i> , 2013, 33, 3762-3779.	2.3	22
80	Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 12-21.e1.	1.9	22
81	What is the role of nephrectomy following complete response to checkpoint inhibitors?. <i>Urology Case Reports</i> , 2018, 18, 60-63.	0.3	20
82	Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma. <i>Journal of Immunology</i> , 2020, 205, 3218-3229.	0.8	20
83	Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 4542-4551.	7.0	19
84	Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e263-e272.	1.9	19
85	Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. <i>PLoS ONE</i> , 2015, 10, e0129233.	2.5	18
86	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100692.	1.2	18
87	An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. <i>Molecular Cell</i> , 2022, 82, 3030-3044.e8.	9.7	18
88	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. <i>Clinical Cancer Research</i> , 2021, 27, 4794-4806.	7.0	17
89	Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).. <i>Journal of Clinical Oncology</i> , 2019, 37, 26-26.	1.6	17
90	Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e9-166.e13.	1.6	17

#	ARTICLE	IF	CITATIONS
91	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. <i>Nature Genetics</i> , 1997, 16, 336-337.	21.4	16
92	A renal cell carcinoma tumorgraft platform to advance precision medicine. <i>Cell Reports</i> , 2021, 37, 110055.	6.4	16
93	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	1.9	14
94	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1221-e1235.	1.9	14
95	Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. <i>Radiographics</i> , 2019, 39, 998-1016.	3.3	14
96	Sunitinib in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3457-3460.	1.6	13
97	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	329.8	13
98	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) <i>TJ ETQq0 0 0 rgBT/Overlock</i>		12
99	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6716-6725.	7.0	12
100	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, 24.	1.4	11
101	mTORC1 activation in childhood ependymoma and response to sirolimus. <i>Journal of Neuro-Oncology</i> , 2011, 103, 797-801.	2.9	10
102	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. <i>Kidney Cancer</i> , 2018, 2, 31-36.	0.4	10
103	Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 485-488.	1.9	9
104	Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 532-532.	1.6	9
105	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, , .	1.9	9
106	Whole-body MRI for metastatic cancer detection using T ₂ -weighted imaging with fat and fluid suppression. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1402-1415.	3.0	8
107	Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma. <i>European Radiology</i> , 2018, 28, 124-132.	4.5	8
108	Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 260-269.	1.9	8

#	ARTICLE	IF	CITATIONS
109	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 5013-5020.	7.0	8
110	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus – Initial Experience Report and Literature Review. <i>Kidney Cancer</i> , 2019, 3, 71-77.	0.4	7
111	Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 154-165.	2.5	7
112	Inflammatory Reaction Secondary to Immune Checkpoint Inhibitor Therapy Mimicking a Post-Operative Brain Abscess. <i>World Neurosurgery</i> , 2019, 129, 354-358.	1.3	6
113	Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e675-e680.	1.9	5
114	Research Translation and Personalized Medicine. , 2012, , 161-191.		5
115	Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 619-619.	1.6	5
116	What morphology can teach us about renal cell carcinoma clonal evolution. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2020, 18, 68-76.	0.1	5
117	DEFOR: depth- and frequency-based somatic copy number alteration detector. <i>Bioinformatics</i> , 2019, 35, 3824-3825.	4.1	4
118	Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	1.9	4
119	Selective Efficacy of Temezirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e321-e323.	1.9	3
120	Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 925-927.	4.9	3
121	Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 5709.	3.7	3
122	Loss of BAP1 and PBRM1 protein expression and its association with clear cell renal cell carcinoma-specific survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 414-414.	1.6	2
123	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022, 6, 69-79.	0.4	2
124	mTORC1 Signaling and Hypoxia. , 2009, , 75-97.		1
125	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 586-586.	1.6	1
126	Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 633-633.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Brain metastases (BMs) from metastatic renal cell carcinoma (RCC) in patients (pts) treated with molecularly targeted agents (MTAs).. Journal of Clinical Oncology, 2012, 30, e15066-e15066.	1.6	0
128	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, TPS4678-TPS4678.	1.6	0
129	Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches.. Journal of Clinical Oncology, 2018, 36, 601-601.	1.6	0
130	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	1.6	0
131	Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 663-663.	1.6	0
132	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 651-651.	1.6	0
133	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
134	The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 632-632.	1.6	0
135	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2019, 17, 94-104.	0.1	0